Ideaya Historical Balance Sheet

IDYA Stock

USD 26.79 0.19 0.71%

Trend analysis of Ideaya Biosciences balance sheet accounts such as Total Current Liabilities of 24.7 M or Total Stockholder Equity of 652.1 M provides information on Ideaya Biosciences' total assets, liabilities, and equity, which is the actual value of Ideaya Biosciences to its prevalent stockholders. By breaking down trends over time using Ideaya Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Ideaya Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ideaya Biosciences is a good buy for the upcoming year.

Ideaya Biosciences Inventory

559.24 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.

About Ideaya Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ideaya Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Ideaya Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ideaya Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ideaya currently owns. An asset can also be divided into two categories, current and non-current.

Ideaya Biosciences Balance Sheet Chart

At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 652.1 M, whereas Other Current Liabilities is forecasted to decline to about 11.3 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Ideaya Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ideaya Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Ideaya Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ideaya Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Ideaya Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ideaya Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 652.1 M, whereas Other Current Liabilities is forecasted to decline to about 11.3 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	17.3M	25.0M	17.0M	11.3M
Total Assets	381.3M	388.0M	649.3M	681.8M

Other Current Liab Total Assets

Ideaya Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.79	0.79	0.99	0.34	0.97	0.77	-0.99	-0.99	0.94	0.99	0.86	0.3	0.13	0.91	0.9	0.89	-0.78	-0.33	0.98	0.89	0.99	0.34	0.99	0.84	0.99
Other Current Liab	0.79		0.82	0.77	0.3	0.86	0.67	-0.74	-0.82	0.74	0.73	0.65	0.08	0.18	0.89	0.88	0.88	-0.34	-0.26	0.86	0.82	0.8	0.68	0.77	0.89	0.8
Total Current Liabilities	0.79	0.82		0.74	0.75	0.85	0.83	-0.76	-0.75	0.56	0.76	0.69	0.09	0.19	0.89	0.77	0.82	-0.3	-0.14	0.84	0.94	0.74	0.79	0.74	0.72	0.78
Total Stockholder Equity	0.99	0.77	0.74		0.26	0.97	0.75	-0.98	-0.99	0.95	0.98	0.86	0.29	0.0	0.89	0.9	0.87	-0.81	-0.46	0.98	0.86	1.0	0.27	1.0	0.84	0.98
Other Liab	0.34	0.3	0.75	0.26		0.38	0.54	-0.34	-0.25	0.02	0.34	0.25	-0.17	0.1	0.47	0.26	0.41	0.05	0.18	0.35	0.62	0.26	0.65	0.26	0.12	0.34
Net Tangible Assets	0.97	0.86	0.85	0.97	0.38		0.84	-0.95	-0.97	0.88	0.95	0.82	0.26	0.01	0.93	0.92	0.91	-0.67	-0.45	1.0	0.93	0.97	0.48	0.97	0.89	0.96
Property Plant And Equipment Net	0.77	0.67	0.83	0.75	0.54	0.84		-0.75	-0.78	0.58	0.76	0.58	0.53	0.1	0.83	0.73	0.8	-0.37	-0.23	0.84	0.89	0.72	0.65	0.75	0.76	0.79
Net Debt	-0.99	-0.74	-0.76	-0.98	-0.34	-0.95	-0.75		0.98	-0.93	-1.0	-0.89	-0.33	-0.12	-0.9	-0.9	-0.87	0.8	0.33	-0.95	-0.88	-0.98	-0.27	-0.98	-0.82	-0.98
Retained Earnings	-0.99	-0.82	-0.75	-0.99	-0.25	-0.97	-0.78	0.98		-0.95	-0.98	-0.83	-0.36	-0.09	-0.92	-0.93	-0.91	0.76	0.38	-0.98	-0.88	-0.99	-0.33	-0.99	-0.89	-0.99
Accounts Payable	0.94	0.74	0.56	0.95	0.02	0.88	0.58	-0.93	-0.95		0.92	0.78	0.27	0.09	0.8	0.85	0.82	-0.86	-0.38	0.9	0.71	0.96	0.12	0.95	0.8	0.94
Cash	0.99	0.73	0.76	0.98	0.34	0.95	0.76	-1.0	-0.98	0.92		0.89	0.33	0.11	0.89	0.87	0.86	-0.81	-0.34	0.96	0.87	0.98	0.27	0.98	0.8	0.98
Non Current Assets Total	0.86	0.65	0.69	0.86	0.25	0.82	0.58	-0.89	-0.83	0.78	0.89		0.3	0.19	0.77	0.77	0.64	-0.71	-0.33	0.82	0.74	0.85	0.22	0.86	0.75	0.79
Non Currrent Assets Other	0.3	0.08	0.09	0.29	-0.17	0.26	0.53	-0.33	-0.36	0.27	0.33	0.3		0.26	0.3	0.32	0.28	-0.22	-0.01	0.29	0.29	0.25	0.02	0.29	0.47	0.28
Other Assets	0.13	0.18	0.19	0.0	0.1	0.01	0.1	-0.12	-0.09	0.09	0.11	0.19	0.26		0.16	0.03	0.11	0.0	0.81	0.05	0.08	0.04	0.33	0.0	0.11	0.11
Cash And Short Term Investments	0.91	0.89	0.89	0.89	0.47	0.93	0.83	-0.9	-0.92	0.8	0.89	0.77	0.3	0.16		0.97	0.97	-0.48	-0.25	0.94	0.97	0.89	0.57	0.89	0.9	0.91
Common Stock Shares Outstanding	0.9	0.88	0.77	0.9	0.26	0.92	0.73	-0.9	-0.93	0.85	0.87	0.77	0.32	0.03	0.97		0.95	-0.53	-0.4	0.92	0.91	0.9	0.41	0.9	0.94	0.9
Short Term Investments	0.89	0.88	0.82	0.87	0.41	0.91	0.8	-0.87	-0.91	0.82	0.86	0.64	0.28	0.11	0.97	0.95		-0.48	-0.24	0.91	0.94	0.88	0.52	0.87	0.87	0.92
Long Term Debt Total	-0.78	-0.34	-0.3	-0.81	0.05	-0.67	-0.37	0.8	0.76	-0.86	-0.81	-0.71	-0.22	0.0	-0.48	-0.53	-0.48		0.36	-0.69	-0.44	-0.81	0.24	-0.81	-0.45	-0.77
Non Current Liabilities Total	-0.33	-0.26	-0.14	-0.46	0.18	-0.45	-0.23	0.33	0.38	-0.38	-0.34	-0.33	-0.01	0.81	-0.25	-0.4	-0.24	0.36		-0.42	-0.27	-0.42	0.14	-0.46	-0.41	-0.32
Capital Surpluse	0.98	0.86	0.84	0.98	0.35	1.0	0.84	-0.95	-0.98	0.9	0.96	0.82	0.29	0.05	0.94	0.92	0.91	-0.69	-0.42		0.92	0.97	0.46	0.98	0.9	0.97
Other Current Assets	0.89	0.82	0.94	0.86	0.62	0.93	0.89	-0.88	-0.88	0.71	0.87	0.74	0.29	0.08	0.97	0.91	0.94	-0.44	-0.27	0.92		0.85	0.62	0.86	0.83	0.89
Other Stockholder Equity	0.99	0.8	0.74	1.0	0.26	0.97	0.72	-0.98	-0.99	0.96	0.98	0.85	0.25	0.04	0.89	0.9	0.88	-0.81	-0.42	0.97	0.85		0.28	1.0	0.84	0.99
Total Liab	0.34	0.68	0.79	0.27	0.65	0.48	0.65	-0.27	-0.33	0.12	0.27	0.22	0.02	0.33	0.57	0.41	0.52	0.24	0.14	0.46	0.62	0.28		0.27	0.49	0.36
Net Invested Capital	0.99	0.77	0.74	1.0	0.26	0.97	0.75	-0.98	-0.99	0.95	0.98	0.86	0.29	0.0	0.89	0.9	0.87	-0.81	-0.46	0.98	0.86	1.0	0.27		0.84	0.98
Property Plant And Equipment Gross	0.84	0.89	0.72	0.84	0.12	0.89	0.76	-0.82	-0.89	0.8	0.8	0.75	0.47	0.11	0.9	0.94	0.87	-0.45	-0.41	0.9	0.83	0.84	0.49	0.84		0.82
Total Current Assets	0.99	0.8	0.78	0.98	0.34	0.96	0.79	-0.98	-0.99	0.94	0.98	0.79	0.28	0.11	0.91	0.9	0.92	-0.77	-0.32	0.97	0.89	0.99	0.36	0.98	0.82

Click cells to compare fundamentals

Ideaya Biosciences Account Relationship Matchups

Ideaya Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	113.0M	298.3M	381.3M	388.0M	649.3M	681.8M
Other Current Liab	63K	7.0M	17.3M	25.0M	17.0M	11.3M
Total Current Liabilities	6.9M	38.6M	45.2M	31.7M	27.1M	24.7M
Total Stockholder Equity	100.4M	198.3M	301.5M	349.5M	621.1M	652.1M
Other Liab	34K	56.2M	31.2M	5.2M	6.0M	5.7M
Net Tangible Assets	100.4M	198.3M	301.5M	349.5M	401.9M	422.0M
Property Plant And Equipment Net	9.7M	9.5M	8.7M	9.0M	8.4M	8.5M
Net Debt	(27.3M)	(65.3M)	(86.9M)	(65.2M)	(154.1M)	(146.4M)
Retained Earnings	(92.5M)	(127.0M)	(176.7M)	(235.4M)	(348.4M)	(330.9M)
Accounts Payable	709K	953K	2.1M	4.3M	6.6M	6.9M
Cash	34.1M	72.0M	92.0M	68.6M	157.0M	164.9M
Non Current Assets Total	12.5M	9.7M	130.4M	17.5M	116.7M	122.5M
Non Currrent Assets Other	1.3M	82K	397K	205K	782K	416.2K
Other Assets	122K	188K	397K	205K	184.5K	239.2K
Cash And Short Term Investments	100.5M	283.6M	368.1M	373.1M	525.1M	275.6M
Common Stock Total Equity	2K	3K	4K	5K	5.8K	6.0K
Common Stock Shares Outstanding	20.2M	24.7M	35.3M	41.4M	57.5M	32.6M
Short Term Investments	64.9M	211.5M	154.7M	296.2M	368.1M	184.2M
Liabilities And Stockholders Equity	113.0M	298.3M	381.3M	388.0M	649.3M	681.8M
Non Current Liabilities Total	5.7M	61.4M	34.7M	6.8M	1.1M	1.1M
Capital Surpluse	192.8M	325.3M	479.0M	587.7M	675.9M	709.7M
Capital Lease Obligations	6.8M	6.7M	5.2M	3.5M	2.9M	3.9M
Other Current Assets	2.7M	6.3M	6.2M	5.4M	7.5M	4.6M
Other Stockholder Equity	79.8M	325.3M	479.0M	587.7M	968.9M	1.0B
Total Liab	113.0M	298.3M	381.3M	388.0M	28.2M	26.8M
Net Invested Capital	100.4M	198.3M	301.5M	349.5M	621.1M	652.1M
Property Plant And Equipment Gross	9.7M	4.3M	14.3M	16.5M	18.0M	11.3M
Total Current Assets	100.5M	288.6M	251.0M	370.5M	532.6M	559.3M
Accumulated Other Comprehensive Income	65K	7K	(712K)	(2.9M)	562K	590.1K
Non Current Liabilities Other	34K	12K	34.7M	6.8M	7.8M	7.7M
Net Working Capital	94.7M	250.0M	205.8M	338.7M	505.5M	530.8M
Short Term Debt	1.1M	3.1M	3.4M	3.7M	3.5M	2.3M
Common Stock	2K	3K	4K	5K	7K	3.6K
Property Plant Equipment	9.7M	9.5M	4.8M	6.5M	7.5M	7.2M
Capital Stock	2K	3K	4K	5K	7K	3.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Ideaya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ideaya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ideaya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ideaya Biosciences Stock:

How To Invest In Ideaya

Details

Is Ideaya Stock a good investment?

Details

What is Ideaya Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.33)

Revenue Per Share

0.051

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.16)

Return On Equity

(0.21)

The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ideaya Historical Balance Sheet

Ideaya Biosciences Inventory

559.24 Million

About Ideaya Balance Sheet Analysis

Ideaya Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Ideaya Biosciences balance sheet Correlations

Ideaya Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ideaya Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Surpluse	+ 1.0	Net Tangible Assets
Net Invested Capital	+ 1.0	Other Stockholder Equity
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Retained Earnings
Net Invested Capital	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Total Stockholder Equity
Retained Earnings	- 0.99	Total Assets